AstraZeneca reinforces leadership in breast cancer at SABCS 2021 with new data underscoring ambition to redefine cancer care
Data from DESTINY-Breast03 will reaffirm the efficacy of Enhertu in treating HER2-positive metastatic breast cancer, including patients with stable brain metastases.Extensive portfolio of nine approved and potential new medicines to be featured across subtypes and stages of disease, including data for novel combinations.AstraZeneca will underscore its ambition to redefine care with new data from across its portfolio of innovative medicines at the 2021 San Antonio Breast Cancer Symposium (SABCS) 7-10 December 2021. Fourteen AstraZeneca medicines and potential new medicines from the